OnKure Therapeutics (OKUR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Apr, 2026Executive summary
Annual meeting scheduled for June 3, 2026, with voting open until June 2, 2026, at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by May 20, 2026.
Meeting will be held virtually, allowing remote participation and voting.
Voting matters and shareholder proposals
Election of three Class II directors to serve until the 2029 annual meeting.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Amendment and restatement of the 2024 Equity Incentive Plan to increase reserved shares by approximately 8% and remove the annual limit from the evergreen provision.
Proxies authorized to vote on other business as may arise during the meeting.
Board of directors and corporate governance
Nominees for Class II director positions: R. Michael Carruthers, Valerie M. Jansen, M.D., Ph.D., and Edward T. Mathers.
Latest events from OnKure Therapeutics
- Advancing best-in-class PI3Kα pan-mutant inhibitors for major oncology and rare disease markets.OKUR
Corporate presentation - Q2 2026 net loss was $15.3M; $176M cash runway supports IND filings into 2029.OKUR
Q2 2026 - Pan-mutant selective PI3Kα inhibitors advance toward IND, showing strong efficacy and safety.OKUR
KOL event - Directors elected, auditor ratified, and equity plan amended with all proposals approved.OKUR
AGM 2026 - Q1 2026 net loss was $15.2M; $192.1M cash supports PI3Ka pipeline and operations into 2029.OKUR
Q1 2026 - 36.1 million shares registered for resale after $150M private placement; financial risks remain.OKUR
Registration filing - Advancing best-in-class PI3Kα pan-mutant inhibitors for major oncology and rare disease markets.OKUR
Corporate presentation - Shareholders will vote on director elections, auditor ratification, and an expanded equity plan.OKUR
Proxy filing - Key clinical milestones and a strong cash position highlight progress in PI3Ka-targeted therapies.OKUR
Q4 2025